The role of delamanid in the treatment of drug-resistant tuberculosis

Joseph M. Lewis, Derek James Sloan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

49 Citations (Scopus)


Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

Original languageEnglish
Pages (from-to)779-791
Number of pages13
JournalTherapeutics and Clinical Risk Management
Publication statusPublished - 13 May 2015


  • Delamanid
  • OPC-67683
  • Tuberculosis
  • Drug resistance
  • MDR-TB


Dive into the research topics of 'The role of delamanid in the treatment of drug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this